StockData
Molecular Partners AG logo

Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.86+0.16 (+5.98%)

Close on Nov 17, 2026Market cap $115.47MP/E –Yield –

Molecular Partners r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CHF 40.19M, down 17.3% from the year before. The highest annual figure on record is CHF 56.08M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 40.19M-17.3%
FY2024Dec 31, 2024CHF 48.60M-0.4%
FY2023Dec 31, 2023CHF 48.78M-3.9%
FY2022Dec 31, 2022CHF 50.75M-8.9%
FY2021Dec 31, 2021CHF 55.72M-0.6%
FY2020Dec 31, 2020CHF 56.08M+28.9%
FY2019Dec 31, 2019CHF 43.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026CHF 9.61M-23.6%
Q2 FY2025Jun 30, 2025CHF 10.71M–
Q2 FY2024Jun 30, 2024CHF 13.09M–
Q2 FY2023Jun 30, 2023CHF 11.63M–
Q2 FY2022Jun 30, 2022CHF 12.57M–

More Molecular Partners figures

See a number that looks wrong?